Evidence map›Paper›PMID 40221395›Full record

ArticleNature communications2025

Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses.

Sebastian G Huayamares, Liming Lian, Regina Rab, Yuning Hou, Afsane Radmand, Hyejin Kim, Ryan Zenhausern, Bhagelu R Achyut, Melissa Gilbert Ross, Melissa P Lokugamage and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sebastian G HuayamaresWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-2859-3074
Liming LianWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Regina RabDepartment of Pediatrics, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-0293-4694
Yuning HouWinship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9894-3821
Afsane RadmandPetit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.
Hyejin KimWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7937-2733
Ryan ZenhausernWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Bhagelu R AchyutDepartment of Pediatrics, Emory University, Atlanta, GA, USA.
Melissa Gilbert RossWinship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-1960-8302
Melissa P LokugamageWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
David LoughreyWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Hannah E PeckWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Elisa Schrader EcheverriWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-4094-2054
Alejandro J Da Silva SanchezPetit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.ORCID http://orcid.org/0009-0005-7476-5406
Aram ShajiiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Andrea LiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Karen E TiegreenWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Philip J SantangeloWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA.
Eric J SorscherDepartment of Pediatrics, Emory University, Atlanta, GA, USA. esorscher@emory.edu.ORCID http://orcid.org/0000-0001-9341-3354
James E DahlmanWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA, USA. james.dahlman@emory.edu.ORCID http://orcid.org/0000-0001-7580-436X

Funding

Intratumoral generation of F-Ade to ablate low growth fraction HNSCCR01DE026941 · NIDCR · EMORY UNIVERSITY · PI SORSCHER, ERIC J · 2017 to 2021
$2.3M
NIDCR NIH HHS R01 DE026941U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01DE026941
6 · The paper itself

Abstract

Most cancer patients diagnosed with late-stage head and neck squamous cell carcinoma are treated with chemoradiotherapy, which can lead to toxicity. One potential alternative is tumor-limited conversion of a prodrug into its cytotoxic form. We reason this could be achieved by transient and tumor-specific expression of purine nucleoside phosphorylase (PNP), an Escherichia coli enzyme that converts fludarabine into 2-fluoroadenine, a potent cytotoxic drug. To efficiently express bacterial PNP in tumors, we evaluate 44 chemically distinct lipid nanoparticles (LNPs) using species-agnostic DNA barcoding in tumor-bearing mice. Our lead LNP, designated LNP intratumoral (LNP

Indexed as

Antineoplastic AgentsEscherichia coli ProteinsHead and Neck NeoplasmsNanoparticlesProdrugsPurine-Nucleoside PhosphorylaseAnimalsCell Line, TumorDrug Delivery SystemsEscherichia coliFemaleHumansMiceRNA, MessengerVidarabineVidarabine PhosphateAntineoplastic AgentsEscherichia coli Proteinsfludarabinefludarabine phosphateProdrugsPurine-Nucleoside PhosphorylaseRNA, MessengerVidarabineVidarabine Phosphate

Identifiers

PMID40221395
PMCPMC11993580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.